09/14/2009 Achaogen Announces ACHN-490 Clinical Data at the 49th Annual ICAAC Meeting

-Achaogen’s Neoglycoside Shown to be Well-Tolerated in Phase 1, Dose-Ranging Clinical Trial-
-Additional Preclinical Data Validates ACHN-490’s Consistent Activity Against Gram-Negative and Aminoglycoside-Resistant Bacteria-

08/25/2009 Achaogen Appoints John C. Doyle to the Newly Created Position of Chief Operating Officer
Achaogen announced today the appointment of John C. Doyle to the newly created position of chief operating officer.

08/01/2009 Betting the Pharma
"ACHAOGEN: SUPERBUG SWATTER  |  This San Francisco biotech is developing a new antibiotic arsenal against the growing global superbug crisis, including methicillin-resistant Staphylococcus aureus (MRSA) and Gram-negative bacteria."
Walter Armstrong
PharmaExec
August 1, 2009
Read more...

02/09/2010 Antistaphylococcal Activity of ACHN-490 Tested Alone and in Combination with Other Agents by Time-Kill Assay
Gengrong Lin, Lois M. Ednie, and Peter C. Appelbaum
Antimicrobial Agents and Chemotherapy, doi:10.1128/AAC.01350-09
Access this publication at aac.asm.org

10/01/2009 ACHN-490, a Neoglycoside with Potent In Vitro Activity against Multidrug-Resistant Klebsiella pneumoniae Isolates
Andrea Endimiani, Kristine M. Hujer, Andrea M. Hujer, Eliana S. Armstrong, Yuvraj Choudhary, James B. Aggen, and Robert A. Bonomo
Antimicrobial Agents and Chemotherapy, October 2009, p. 4504-4507, Vol. 53, No. 10
Access this publication at aac.asm.org

09/13/2009 Activity of the Neoglycoside ACHN-490 Against a Contemporary Collection of Clinical Isolates Including Antimicrobial-Resistant Strains
RN Jones, ES Armstrong, JB Aggen, DJ Biedenbach, GH Miller
JMI Laboratories, Achaogen Inc.
ICAAC 2009, poster # F1-846a

03/06/2010 The Spread of Superbugs
"But now we’re seeing increasing numbers of superbugs that survive antibiotics. One of the best-known — MRSA, a kind of staph infection — kills about 18,000 Americans annually."
Nichalas D. Kristof
New York Times
March 6, 2010
Read more...

02/26/2010 Rising Threat of Infections Unfazed by Antibiotics
"...for a combination of business reasons and scientific challenges, the pharmaceuticals industry is pursuing very few drugs for Acinetobacter and other organisms of its type, known as Gram-negative bacteria. Meanwhile, the germs are evolving and becoming ever more immune to existing antibiotics."
Andrew Pollack
New York Times
February 26, 2010
Read more...

02/26/2010 Deadly Germs Largely Ignored By Drug Firms
"It is likely to be several years before new drugs to treat Gram-negative infections are available. A report last September by European health authorities found only six novel drugs in clinical trials that might work against at least one Gram-negative organism, compared with 13 for Gram-positive bacteria."
Andrew Pollack
New York Times
February 26, 2010
Read more...